Skip to main content
AmigoFish

Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist

From Pharmaceutical Executive · · 2 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.

Back to Pharmaceutical Executive · Report a problem